Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Utrecht – page 35

616 clinical trials in Utrecht, The Netherlands across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Utrecht at a glance
616
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

616 trials in Utrecht

Open in trial search

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Incyte Corp.

Spinal muscular atrophy

Not recruiting

Study on the Safety and Efficacy of RO7204239 and Risdiplam for Patients with Spinal Muscular Atrophy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Sponsor:F. Hoffmann-La Roche AG

Urticaria chronic+2

Not recruiting

Study on Remibrutinib for Adults with Chronic Inducible Urticaria Uncontrolled by H1-Antihistamines

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Squamous cell carcinoma of head and neck

Not recruiting

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Squamous cell carcinoma of head and neck

Not recruiting

Study of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Genmab A/S

Systemic lupus erythematosus+1

Not recruiting

Study on the Effects of Belimumab and Rituximab for Patients with Severe Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Cardiac amyloidosis

Not recruiting

Study on the Safety of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy Who Completed a Previous Trial

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis Hydrochloride
  • Sponsor:Eidos Therapeutics Inc.

Osteogenesis imperfecta

Not recruiting

Study on the Safety and Effectiveness of BOOST Cells for Treating Severe Osteogenesis Imperfecta in Children Before and After Birth

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Allogeneic Fetal Mesenchymal Stem Cells
  • Sponsor:Karolinska Institutet

Dermatitis atopic

Not recruiting

Study on Tralokinumab for Children Aged 6-11 with Moderate-to-Severe Atopic Dermatitis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Tralokinumab
  • Sponsor:Leo Pharma A/S

Crohn's disease

Not recruiting

Study on the Effects of Etrasimod Arginine for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Etrasimod Arginine
  • Sponsor:Arena Pharmaceuticals Inc.

Inflammatory bowel disease

Not recruiting

Study Comparing Infliximab Alone or with Immunosuppressive Drugs for Moderate to Severe Crohn's Disease Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Amsterdam UMC Stichting

Non-small cell lung cancer

Not recruiting

Study of reduced pembrolizumab dosing compared to standard dose in patients with advanced non-small cell lung cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Stichting Radboud University Medical Center

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Utrecht

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on TTR amyloidosis and heart disease treatments, investigating new therapeutic approaches for cardiac conditions. Clinical trials evaluate novel medications for improving patient mobility and cardiac function.

  • Heart Disease Management
  • Cardiac Biomarkers
  • Treatment Efficacy

Research aims to enhance quality of life for patients with hereditary and wild-type ATTR cardiomyopathy.

02 Cancer Research

Comprehensive studies in gastric cancer, bladder cancer, and neuroblastoma, exploring innovative treatment combinations and diagnostic methods.

  • Immunotherapy Applications
  • Targeted Therapies
  • Diagnostic Imaging

Advanced trials combining established treatments with novel approaches to improve patient outcomes.

03 Neurological Disorders

Groundbreaking research in Amyotrophic Lateral Sclerosis and chronic inflammatory conditions, focusing on innovative treatments and disease modification strategies.

  • Gene-Targeted Therapies
  • Neurological Function
  • Disease Progression

Studies aim to develop effective treatments for rare and challenging neurological conditions.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.